BiotechTube

Retifanlimab + All-trans retinoic acid

Phase 2Recruiting
0 views this week 0 watching💤 Quiet🏛️Featured in Big Pharma Pipeline
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma

Conditions

Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma

Trial Timeline

Nov 16, 2022 → Jun 1, 2028

NCT ID
NCT05345002

About Retifanlimab + All-trans retinoic acid

Retifanlimab + All-trans retinoic acid is a phase 2 stage product being developed by Incyte for Glioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05345002. Target conditions include Glioma, IDH Mutation, Astrocytoma.

What happened to similar drugs?

0 of 3 similar drugs in Glioma were approved

Approved (0) Terminated (0) Active (3)
🔄Everolimus + ONC201Jazz PharmaceuticalsPhase 3
🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3
🔄safusidenib + PlaceboNuvation BioPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05345002Phase 2Recruiting

Competing Products

20 competing products in Glioma

See all competitors
ProductCompanyStageHype Score
TemozolomideNovocurePhase 1
15
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
29
LY2157299 + LomustineEli LillyPhase 1
29
DS-1001bDaiichi SankyoPhase 2
39
DS-1001bDaiichi SankyoPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
32
Temozolomide and BevacizumabEisaiPhase 2
31
TemozolomideEisaiPhase 2
31
Gliadel Wafer + TemozolomideEisaiPhase 2
31
Palonosetron (PALO)EisaiPhase 2
35
Gliadel/Avastin/CPT-11EisaiPhase 2
27
Lenvatinib + BevacizumabEisaiPhase 2
35
Granisetron + OndansetronKyowa KirinPhase 2
27
Binimetinib 15 MGOno PharmaceuticalPhase 2
42
EnzastaurinEli LillyPhase 2
35
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
32
Abemaciclib + TemozolomideEli LillyPhase 2
39
DSP-0390Sumitomo PharmaPhase 1
36
DSP-0390Sumitomo PharmaPhase 1
33